Immuno-Oncology | Specialty

Immunotherapy in Melanoma: What Does the Future Hold?

June 25th 2015

Howard L. Kaufman, MD, discusses the rapidly advancing immunotherapy armamentarium in melanoma.

Interpreting PD-L1 Status Among Key Melanoma Topics at ASCO

June 25th 2015

OncLive sat down with Jason J. Luke, MD, discusses the key areas in the treatment of melanoma discussed at the 2015 ASCO Annual Meeting included selecting appropriate immunotherapy regimens based on PD-L1 status and improving surgical practices.

Future Immunotherapies for Hematologic Malignancies

June 24th 2015

PD-1 Inhibition in Hodgkin's Lymphoma

June 24th 2015

Treatment Advancements in Lymphoma

June 24th 2015

Daratumumab, Vaccines in Multiple Myeloma

June 24th 2015

Elotuzumab in Relapsed/Refractory Multiple Myeloma

June 24th 2015

Measuring Response to Novel Therapies in ALL

June 24th 2015

Blinatumomab in Philadelphia Chromosome-Negative ALL

June 24th 2015

Rituximab, Obinutuzumab, and Ofatumumab in CLL

June 24th 2015

Immunotherapy-Related Adverse Events

June 24th 2015

Responses With Immunotherapy Versus Chemotherapy

June 24th 2015

Immunotherapy in Hematologic Malignancies

June 24th 2015

Dr. Ernstoff Discusses Nivolumab and Ipilimumab in Advanced Melanoma

June 23rd 2015

Marc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced BRAF-mutated or BRAF wild-type melanoma.

First PD-1 Inhibitor Approved in Europe

June 22nd 2015

The European Commission has approved nivolumab as a treatment for patients with advanced melanoma in the first- and later-line setting regardless of BRAF mutation status, making it the first PD-1 inhibitor to gain approval in Europe.

Practical Advice for Immunotherapy Era Emerges From ASCO

June 22nd 2015

For clinicians, a central message from 2015 ASCO is that a framework for managing immune-related adverse events in patients who receive these immune checkpoint agents is taking shape.

Nivolumab Elicits Durable Responses in Lymphoma

June 19th 2015

Nivolumab continued to show high activity and a good safety profile after more than a year of follow-up in heavily pretreated patients with relapsed or refractory lymphoid malignancies or those with classical Hodgkin lymphoma.

Researchers Explore Immunotherapy With XBP1 Inhibition in Ovarian Cancer

June 17th 2015

Laurie H. Glimcher, MD, discusses the promise of XBP1 inhibition as an immunotherapy strategy in ovarian cancer.

History and Evolution of Immuno-oncology

June 17th 2015

Clinical Trial Design for Immunotherapy

June 17th 2015